Reneuron Investors - RENE

Reneuron Investors - RENE

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Reneuron Group Plc RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 137.50 08:00:29
Open Price Low Price High Price Close Price Previous Close
137.50 135.00 137.50 137.50
more quote information »
Industry Sector

Top Investor Posts

zho: Former City broker Richard Griffiths has been dubbed the ‘Welsh Wizard’ for his stock market bets, and has brought plenty of fellow investors under his spell. So market watchers take note. It has emerged that the Jersey dweller has taken a 7 per cent stake in ReNeuron. The small-cap is a stem cell research specialist which recently raised £15 million to expand a study of its treatment for a degenerative eye disease. The shares have rallied over the last month, up more than 30 per cent at £1.33. Griffiths’ followers will have their eyes trained on this one
supernumerary: Roche has stopped a phase 3 Huntington’s disease clinical trial after an interim review of the data. The preplanned review found no new safety signals associated with Ionis Pharmaceuticals-partnered antisense drug tominersen, suggesting lack of efficacy may have driven the decision to stop the trial. Tominersen, also known as IONIS-HTTRx and RG6042, is designed to reduce production of HTT, the protein that in its mutated form drives the rare genetic, progressive condition Huntington’s. HTT is a validated target, but difficulties drugging the protein via traditional modalities means there remains a major unmet need in Huntington’s, leading companies including Ionis to try to come at the problem from a new angle. Ionis’ work led to a licensing deal with Roche in 2017 and forecasts of $5 billion peak annual sales for antisense therapy tominersen. “Given the unmet medical need, with no therapies approved to slow progression of this rare disease, tominersen was widely acknowledged to be a potential high risk but blockbuster reward asset in Roche's pipeline,” analysts at Jefferies wrote in a note to investors. [ ... ] The failure of tominersen creates a potential opportunity for other developers of Huntington’s drugs. Wave Life Sciences and Takeda are partnered on two antisense therapies that are in phase 1/2 trials. Takeda also recently picked up a preclinical mRNA translation modulator through a deal with Anima Biotech, and Arvinas is exploring the application of its protein degradation platform to the disease.
ayl30: He is obviously not good at selling company to City or potential investors or share price would not be this low. Needs a stronger voice?
dickbush: By its own admission, the RP product is several years away from possible marketing, even assuming success, although moving to phase 3 testing in a year's time might be enough to bring in deals/bidders. The excitement here is exosomes, the latest hot technology in this sector as evidenced by the prices paid for companies in this area. As always with RENE, investors are left in the dark as to how far they are along with proving its success in carrying other molecules to their targets and improving outcomes for patients. This is two years old
pdt: hashertu - I picked up the information on the Investor Conference call a few days ago. There is a recording on their website.
the stigologist: Yes. I wonder if US investors will start getting involved here CDAK Codiak Mkt Cap $500m RENE Mkt Cap is £70m (with £20m cash so EV £50m) This has almost overnight become a mRNA and CRISPR play
dontshootthemessenger: Analyst conference call and webcast A conference call for analysts will be held at 10.00 a.m. on 6 January 2021 to discuss the Company’s recent half year results, the fundraising and outlook for the year ahead. Analysts who require dial-in details please contact Buchanan at A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 6 January 2021 at this link: htTps:// The recorded webcast will also be made available at the investor centre of ReNeuron’s website, htTp://
xow98: Placing RNS ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics , announces its intention to raise gross proceeds of up to GBP13.9 million by means of a placing to institutional and other investors (the "Placing") and a direct subscription with the Company to raise gross proceeds of up to GBP1.1 million (the "Subscription"), in each case at a price of 70 pence per share ("Issue Price"). The net proceeds of the Placing and Subscription will allow the Group, inter alia, to deliver extended clinical data from its ongoing retinitis pigmentosa (RP) Phase 2a study and to deliver proof-of-concept pre-clinical data from ongoing exosome collaborations which could enable potential out-licensing deals, as detailed below more fully.
onceaday: Maybe the CFO is also responsiblle for investor relations? He was originally CEO and has been with the company for decades.
pawelkordala: Volume is super low. This price action means nothing. It was pushed down by 50% by some small retail investors who are not patient enough to wait for the new data from clinical trails. Some people probably prefer hot covid stocks...
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210413 09:55:35